Novartis skin cancer drug shrinks tumors in Phase II trial

ZURICH (Reuters) - An experimental drug from Novartis markedly shrank tumors in patients with advanced basal cell carcinoma, the most common form of skin cancer, according to the results of a mid-stage study published on Sunday.

via Reuters: Health News Read More Here..